New look matches focus on transforming GI health ST. LOUIS, MISSOURI (October 3, 2022) | Geneoscopy today announced a corporate rebrand and launch. The rebranding
Trial Enrollment Over Indexes in Traditionally Under-Represented Black Community ST. LOUIS, Aug. 23, 2022 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests
ST. LOUIS, MISSOURI (JULY 19, 2022) | Earlier this year, President Joe Biden announced plans to reignite the Cancer Moonshot with renewed leadership and new ambitious
ST. LOUIS, June 21, 2022 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced the formation of
Data at 2022 Digestive Disease Week Meeting Also Shows RNA-FIT Test to Be Cost-Effective ST. LOUIS, May 23, 2022 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on
Trial Enrollment Data Presented at 2022 ASCO Gastrointestinal Cancers Symposium ST. LOUIS, Jan. 20, 2022 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on the development of diagnostic
Study Results Show Diagnostic Accurately Detects Colorectal Cancer and Precancerous Adenomas With High Sensitivity ST. LOUIS–(BUSINESS WIRE)–Geneoscopy Inc., a life sciences company that develops diagnostic
Funding to support U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand diagnostic product pipeline ST. LOUIS, Nov. 16, 2021 /PRNewswire/ — Geneoscopy Inc., a life sciences company
Seasoned medical affairs executive to advance company’s diagnostics product pipeline ST. LOUIS, Mo., Oct. 18, 2021 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on the development
